Daraxonrasib Plus Chemotherapy in First-Line Pancreatic Cancer: 61% Response, 12.8 Months Progression-Free

In this article
RAS Inhibitor Plus Chemotherapy in First Line: High Response in 61 Patients, but No Comparison Yet
According to the sponsor update that Revolution Medicines published on November 19, 2026 (02:05 on November 20, Türkiye time), daraxonrasib (RASONQUE) combined with gemcitabine and nab-paclitaxel produced, in 61 previously untreated patients with metastatic pancreatic cancer, a confirmed response rate of 60.7%, a median progression-free survival of 12.8 months and an estimated 12-month survival of 76.6%. The data were presented at the EORTC-NCI-AACR (ENA 2026) symposium in Barcelona. These numbers are among the strongest signals I have seen so far in the first line; but they come from an open-label phase 1/2 study without a control arm, and no peer-reviewed publication exists yet. Whether the combination is truly superior to standard chemotherapy will be shown by the randomized phase 3 RASolute 303 trial. I covered the phase 3 results of daraxonrasib in the second line in my RASolute 302 article, the FDA approval of August 2026 in this article, and the resistance mechanisms in my daraxonrasib resistance article (all three in Turkish).
- What was studied? In the open-label phase 1/2 RMC-GI-102 study, 61 patients with first-line metastatic pancreatic cancer received daraxonrasib 200 mg once daily with standard gemcitabine and nab-paclitaxel (GnP). There is no control arm; data cutoff was September 28, 2026, with a median follow-up of 18.3 months.
- Result: Confirmed response rate 60.7% (95% CI 47.3–72.9), complete response 8.2%, disease control 90.2%, median duration of response 11.1 months, median progression-free survival 12.8 months, alive at month 12 76.6%. Median overall survival has not yet been reported.
- How to read it? Well above historical GnP data (response 23–36%, progression-free survival 5.5–5.6 months, 1-year survival 35–40%); but this is an indirect comparison. Patient selection and the small sample can make results look better than they are.
- In practice: Daraxonrasib is approved today only in previously treated patients (or those not suitable for multi-agent chemotherapy). The first-line combination is experimental; for these patients the best route, if eligible, is a clinical trial such as RASolute 303.
Why Does This Topic Matter?
Pancreatic cancer is a disease in which about 80% of patients can no longer be operated on at diagnosis, and 5-year survival in the metastatic stage stays at only about 3% (pancreatic cancer symptoms, stages and treatment, why is early diagnosis still hard?; both in Turkish). In metastatic disease, first-line treatment has relied on chemotherapy for more than ten years: FOLFIRINOX, gemcitabine with nab-paclitaxel, and NALIRIFOX, approved by the FDA in 2024 (FOLFIRINOX and gemcitabine, the NALIRIFOX regimen; both in Turkish). With these regimens, median overall survival stays between 8.5 and 11.1 months.
More than 90% of pancreatic cancers carry a mutation in the KRAS gene, and the RAS protein was considered "undruggable" for decades (the effect of different KRAS mutations, what is the KRAS G12C mutation?; both in Turkish). Daraxonrasib changed this picture by roughly doubling overall survival in the second line. The question now is: if this drug moves to the first line together with chemotherapy, will patients live longer? The November update gives a hopeful but not yet conclusive answer.
- Yes: Daraxonrasib is the first RAS inhibitor to receive FDA approval in pancreatic cancer (August 26, 2026, previously treated patients). The FDA described it as a "first-in-class" targeted therapy.
- No: First-line daraxonrasib plus chemotherapy data are not being announced for the first time; the results of the first 40 patients of this cohort were presented at AACR in April 2026. The November data are an update with more patients and longer follow-up.
- Not yet: The first-line combination is not approved in any country. According to the company, the FDA granted this combination Breakthrough Therapy status in the first line; this is not an approval, but an accelerated-review designation.
What Is Daraxonrasib?
Daraxonrasib (RASONQUE) is a once-daily oral tablet that targets the active "on" (RAS-ON) state of the RAS protein. It acts on several RAS types, not on a single mutation. The FDA approved it on August 26, 2026 in previously treated metastatic pancreatic cancer; first-line use is still under investigation.
RAS works like an on-off switch that tells the cell to "grow and divide". When there is a mutation, the switch gets stuck in the on position. The first KRAS drugs, such as sotorasib and adagrasib, targeted only the G12C mutation and the "off" state of the protein; this mutation occurs in 1–2% of pancreatic cancers. New drugs are being developed for the most common pancreatic cancer mutations, G12D, G12V and G12R (KRAS G12D-targeted therapies, setidegrasib; both in Turkish). Daraxonrasib takes a different path: inside the cell it binds the protein cyclophilin A, sticks to RAS in its on state and blocks signal transmission. That is why it can act regardless of the mutation type; the FDA approval does not require RAS testing either.
What Was Done in the RMC-GI-102 Study?
RMC-GI-102 is an open-label phase 1/2 study with cohorts in which daraxonrasib is used together with different drugs. In the first-line cohort that is the subject of this article, 61 patients with pancreatic cancer who had not been treated before for metastatic disease received daraxonrasib 200 mg once daily together with gemcitabine and nab-paclitaxel on days 1 and 15 of 28-day cycles. The dose used in the combination is lower than the 300 mg dose approved as monotherapy in the second line. The data are being presented by Dr. Wungki Park of Memorial Sloan Kettering at ENA 2026 on November 20, 2026 (what is a clinical trial?, in Turkish).
Figure 1 · Design of the RMC-GI-102 first-line cohort
Phase 1/2, open-label, single-arm
What Changed from April to November?
At the AACR meeting in April 2026, the first 40 patients of this cohort were presented. The November update added 21 more patients and longer follow-up. Maintaining the response rate in more patients suggests that the first results were not a coincidence. In April only month-6 data were available; now, for the first time, median progression-free survival and the 12-month survival estimate have been announced.
| Measure | April 2026 (AACR) | November 2026 (ENA) |
|---|---|---|
| Number of patients | 40 | 61 |
| Confirmed response rate | 58% (95% CI 41–73) | 60.7% (95% CI 47.3–72.9) |
| Complete response | 1 patient | 8.2% (about 5 patients) |
| Progression-free survival | At month 6: 84% | Median 12.8 months (95% CI 10.8–18.4) |
| Overall survival | At month 6: 90% | At month 12: 76.6% (95% CI 63.7–85.4) |
| Duration of response | Not reported | Median 11.1 months |
How Strong Are These Results?
When I put the numbers next to historical chemotherapy data, the difference looks striking. In the MPACT trial, gemcitabine with nab-paclitaxel gave a median progression-free survival of 5.5 months and 1-year survival of 35%; in NAPOLI-3, the same combination gave progression-free survival of 5.6 months and 1-year survival of 39.5%. With NALIRIFOX, considered the strongest chemotherapy regimen today, median progression-free survival is 7.4 months and 1-year survival 45.6%. With the daraxonrasib combination, progression-free survival is 12.8 months and 1-year survival 76.6% (the best results achieved so far in pancreatic cancer, in Turkish).
Median progression-free survival: an indirect look
First-line metastatic pancreatic cancer; months. The first bar is single-arm phase 1/2 data.
GnP: gemcitabine + nab-paclitaxel. Daraxonrasib data are from the company update (ENA 2026, data cutoff September 28, 2026); the others are from randomized phase 3 trials. Comparison across different studies is indirect; patient groups, prior treatments and follow-up times differ.
Patients alive at month 12: an indirect look
First-line metastatic pancreatic cancer; percentage of patients.
For daraxonrasib, 76.6% is an estimate (confidence interval 63.7–85.4%); median overall survival has not yet been reported. Comparison across different studies is indirect; patient groups, prior treatments and follow-up times differ.
But this comparison is indirect and can be misleading. Patients in phase 1/2 studies are usually younger, in better general condition and followed at large centers. In a group of 61 patients the confidence intervals are wide: the response rate could in reality be as low as 47%. Response rate and progression-free survival do not replace overall survival. I have seen many pancreatic cancer treatments that gave hope in phase 2 and failed in phase 3. That is why I see these data as "a strong signal", not as proof (why do clinical studies matter?, in Turkish).
Figure 2 · Four traps when reading single-arm results
Why can we not yet say "superior"?
What Are the Side Effects?
The company's November announcement contains no numerical side-effect data for this cohort; it only states that the safety profile is consistent with the known profiles of daraxonrasib and chemotherapy. In the April data for 40 patients, the most common treatment-related side effects of grade 3 or higher were anemia (33%), low neutrophil count (20%) and fatigue (18%). 5% of patients stopped daraxonrasib and 15% stopped chemotherapy because of side effects; no treatment-related loss of life was reported. This picture suggests that the combination does not add a marked burden on top of the known side effects of chemotherapy; but the numbers are small.
The known side effects of daraxonrasib in its approved use (300 mg, alone) are as follows: acne-like rash and skin problems (86%, severe 10%), diarrhea (63%), mouth sores and stomatitis (57%), nausea, fatigue and loss of appetite. Rare but serious risks include bowel perforation (0.9%) and lung inflammation (pneumonitis, 2.4%). Early recognition of these side effects and preventive care are very important; I described the nursing team's role in rash and mouth care in the article I prepared for oncology nurses (in Turkish).
What Is Known in the Second Line?
What makes the first-line data valuable is that the drug has been proven in the second line in a randomized phase 3 trial. In the RASolute 302 trial, 500 previously treated patients were assigned to daraxonrasib (300 mg) or to the physician's choice of chemotherapy. Median overall survival was 13.2 months versus 6.7 months (HR 0.40; 95% CI 0.30–0.53), median progression-free survival 7.2 versus 3.6 months (HR 0.49), and the response rate 30% versus 11%. In other words, the risk of loss of life fell by 60% and median survival lengthened by 6.5 months. These results were published in the New England Journal of Medicine and formed the basis of the August 2026 FDA approval (the 40-year silence was broken, in Turkish).
The biological logic also supports the first line: suppressing the RAS pathway before the tumor has been exposed to chemotherapy and while it has developed less resistance may be more effective. On the other hand, resistance develops within months in most patients who respond in the second line; for this reason, using the drug together with chemotherapy is also seen as a way of delaying resistance.
What Will RASolute 303 Test?
RASolute 303 (NCT07491445), which will give the definitive answer, is a three-arm, randomized, open-label phase 3 trial that began in March 2026 and plans to enroll about 900 patients. Patients with previously untreated metastatic pancreatic cancer are assigned, regardless of RAS mutation status, to daraxonrasib alone, daraxonrasib with GnP, or GnP alone. The primary endpoints are progression-free survival and overall survival, comparing the combination arm with the GnP arm. The primary completion date is projected for April 2028; interim analyses may come earlier.
Figure 3 · Design of the RASolute 303 trial
Phase 3, randomized, three-arm
I want to draw attention to one point: the comparison arm in the trial is GnP; not FOLFIRINOX or NALIRIFOX, which many centers prefer today in young patients in good general condition. Even if the trial is positive, how the combination compares with these more intensive regimens will remain a separate question.
The Situation in Türkiye and What It Means for Patients
Daraxonrasib is not licensed in Türkiye. It was approved in the United States in August 2026 and, according to the company, in the European Union in November 2026, for previously treated patients. An application to obtain the drug from abroad can be made for the second-line indication; but because the first-line combination is not approved in any country, obtaining the drug from abroad should not be expected for that use either. The way to reach this treatment in the first line is clinical trials.
My advice today to patients newly diagnosed with metastatic pancreatic cancer is this: start standard chemotherapy (FOLFIRINOX, NALIRIFOX or GnP) without delay, have genetic tests done on the tumor and in the blood, and ask whether there is a suitable clinical trial. In patients with an inherited BRCA mutation, platinum-containing treatments and options such as olaparib carry particular importance (inherited BRCA testing, olaparib approval; both in Turkish). It should not be forgotten that chemotherapy at an appropriate dose benefits older patients or those in poor general condition as well (chemotherapy in old age, in Turkish). Other approaches such as KRAS-targeted vaccines are also being investigated (vaccine in KRAS-mutant cancers, in Turkish). For risk assessment in people with pancreatic cancer in the family, you can look at this article (in Turkish).
Questions You Can Ask Your Doctor
- Which genetic tests were done on my tumor and blood; do KRAS, BRCA and other changes affect my treatment?
- Which chemotherapy is most suitable for me in the first line: FOLFIRINOX, NALIRIFOX or gemcitabine with nab-paclitaxel?
- Can I take part in RASolute 303 or another clinical trial; where is the nearest center?
- If my disease progresses, could daraxonrasib be an option in the second line; is it possible to obtain the drug from abroad?
- What should I do to prevent side effects such as rash, mouth sores and diarrhea?
- "If the response rate is 60%, 60% of patients are cured." No. Response means the tumor shrinks by a certain percentage; it does not mean the disease has disappeared completely or that life is prolonged.
- "This combination is now the new standard." Not yet. The data come from a 61-patient study without a control arm; the randomized RASolute 303 will show whether it becomes standard.
- "Daraxonrasib works only in a specific KRAS mutation." No. The drug targets the on state of RAS across several mutation types; the FDA approval does not require RAS testing.
- "A new drug is coming, so I will wait before starting chemotherapy." No. In metastatic pancreatic cancer, delaying treatment can cause serious harm; standard treatment should be started on time.
- "Because it is a tablet, it has few side effects." No. Rash, mouth sores and diarrhea are very common and require close follow-up and preventive care.
Frequently Asked Questions
- Can daraxonrasib be used in the first line?
- Not yet. Daraxonrasib is approved only in patients with metastatic pancreatic cancer who were previously treated or are not suitable for multi-agent chemotherapy. Its use together with chemotherapy in the first line is being investigated in clinical trials.
- What are the results of the daraxonrasib and chemotherapy combination?
- In the phase 1/2 RMC-GI-102 study, the confirmed response rate in 61 patients was 60.7%, median progression-free survival 12.8 months and the proportion alive at month 12 76.6%. Because there was no control arm, these results cannot be compared directly with standard chemotherapy.
- What is the RASolute 303 trial?
- It is a randomized phase 3 trial that compares daraxonrasib alone, daraxonrasib with chemotherapy, and chemotherapy alone in about 900 previously untreated patients with metastatic pancreatic cancer. The primary completion date is projected for April 2028.
- Is daraxonrasib available in Türkiye?
- It is not licensed in Türkiye. In the second line, which is the approved indication, an application to obtain the drug from abroad can be considered. Access to first-line use is possible only through clinical trials.
Glossary
- RAS-ON inhibitor
- A group of drugs that target the active, signal-transmitting "on" state of the RAS protein.
- KRAS
- A gene that controls cell growth and is mutated in more than 90% of pancreatic cancers.
- First line
- The first treatment given for metastatic disease.
- GnP
- The chemotherapy combination of gemcitabine and nab-paclitaxel.
- Confirmed response rate
- The share of patients whose tumor shrank by at least 30% and whose response was confirmed on a second scan.
- Progression-free survival
- The time after treatment starts during which the disease does not progress.
- Overall survival
- The time patients live after treatment starts; the most important endpoint.
- Single-arm study
- A study in which all patients receive the same treatment and there is no comparison group.
- Randomized study
- A study in which patients are assigned by chance to different treatment groups; the most reliable method of comparison.
- Confidence interval
- The range in which the true value most likely lies; it widens as the sample gets smaller.
DROZDOGAN Academy Commentary
I have not seen a dataset in years in which the response rate in first-line pancreatic cancer exceeds 60% and 1-year survival exceeds 75%. But this excitement must be carried without forgetting what single-arm studies have taught us in the past.
⚡ Why it matters
Daraxonrasib is the first RAS inhibitor proven in a randomized trial to prolong overall survival in the second line of pancreatic cancer. If it shows a similar difference in the first line, the standard treatment of metastatic pancreatic cancer could change fundamentally after more than a decade.
✅ Strengths
The response rate was maintained even though the number of patients grew from April to November; median follow-up of 18.3 months; 90% disease control and 11.1-month duration of response; the drug being proven in the second line by a phase 3 trial and appearing usable together with chemotherapy.
⚠️ Limits
No control arm; 61 patients; open-label; the data come from a company announcement and a congress presentation, and there is no peer-reviewed publication yet. Detailed side-effect data, patient characteristics, RAS mutation subgroups and median overall survival for this cohort have not been announced. Patient selection can make results look better than they are.
🩺 In practice
In my newly diagnosed patients with metastatic pancreatic cancer I do not delay standard chemotherapy; I request genetic tests on the tumor and in the blood and explain clinical trial options to suitable patients. I do not recommend daraxonrasib in the first line outside a trial. When the disease progresses, I evaluate with my patients the route of obtaining the drug from abroad for access to daraxonrasib in the second line.
❓ Open questions
How much will the combination prolong overall survival compared with GnP? Could daraxonrasib alone be a first-line option without chemotherapy? Where will the combination stand against FOLFIRINOX or NALIRIFOX? In which RAS mutations is the benefit greater? What comes next when resistance develops?
Conclusion: A strong, consistent and hopeful signal; but still without a comparison. The key question, whether this combination lets patients live longer than standard chemotherapy, will be answered by RASolute 303. Until then, the right address in the first line is clinical trials.
- This article was prepared in November 2026.
- First-line data are taken from Revolution Medicines' press release of November 19, 2026 (data cutoff September 28, 2026). The full content of the ENA 2026 presentation and a peer-reviewed publication were not accessible when this article was prepared. The announcement contains no numerical side-effect data for this cohort; side-effect information is based on the April 2026 AACR data and the FDA-approved product information. The April data were taken from secondary news sources.
- Comparisons in the charts are indirect; patient groups, periods and assessment methods differ between studies.
- Diagrams are simplified. The academy commentary is my own. This article is not medical advice; make treatment decisions together with your doctor.
References
- Revolution Medicines. Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026. Press release, November 19, 2026. globenewswire.com
- U.S. Food and Drug Administration. FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma. August 26, 2026. fda.gov
- RASONQUE (daraxonrasib) US prescribing information. accessdata.fda.gov
- Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (RASolute 302). N Engl J Med 2026. doi:10.1056/NEJMoa2605555. PubMed
- Dana-Farber Cancer Institute. RAS(ON) inhibitor doubles median overall survival in results of phase 3 trial for patients with metastatic pancreatic cancer. May 31, 2026. dana-farber.org
- Emerging daraxonrasib data for pancreatic cancer at AACR (April 2026 data). clinicaltrialvanguard.com
- RASolute 303 (NCT07491445): first-line phase 3 study of daraxonrasib and daraxonrasib + GnP. clinicaltrials.ucsf.edu
- Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-1703. doi
- Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3). Lancet 2023;402:1272-1281. doi
- Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-1825. doi
Was this article helpful?
Your feedback helps us improve our content.




